327 related articles for article (PubMed ID: 15471847)
1. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.
Suzuki T; Wu D; Schlachetzki F; Li JY; Boado RJ; Pardridge WM
J Nucl Med; 2004 Oct; 45(10):1766-75. PubMed ID: 15471847
[TBL] [Abstract][Full Text] [Related]
2. Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology.
Lee HJ; Boado RJ; Braasch DA; Corey DR; Pardridge WM
J Nucl Med; 2002 Jul; 43(7):948-56. PubMed ID: 12097468
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors.
Kurihara A; Deguchi Y; Pardridge WM
Bioconjug Chem; 1999; 10(3):502-11. PubMed ID: 10346884
[TBL] [Abstract][Full Text] [Related]
4. Imaging gene expression in regional brain ischemia in vivo with a targeted [111in]-antisense radiopharmaceutical.
Suzuki T; Zhang Y; Zhang YF; Schlachetzki F; Pardridge WM
Mol Imaging; 2004 Oct; 3(4):356-63. PubMed ID: 15802053
[TBL] [Abstract][Full Text] [Related]
5. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo.
Pardridge WM; Boado RJ; Kang YS
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5592-6. PubMed ID: 7777554
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates.
Jia F; Figueroa SD; Gallazzi F; Balaji BS; Hannink M; Lever SZ; Hoffman TJ; Lewis MR
J Nucl Med; 2008 Mar; 49(3):430-8. PubMed ID: 18287262
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS.
Boado RJ; Tsukamoto H; Pardridge WM
J Pharm Sci; 1998 Nov; 87(11):1308-15. PubMed ID: 9811482
[TBL] [Abstract][Full Text] [Related]
8. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
Deguchi Y; Kurihara A; Pardridge WM
Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene.
Gallazzi F; Wang Y; Jia F; Shenoy N; Landon LA; Hannink M; Lever SZ; Lewis MR
Bioconjug Chem; 2003; 14(6):1083-95. PubMed ID: 14624621
[TBL] [Abstract][Full Text] [Related]
10. Antisense imaging of gene expression in the brain in vivo.
Shi N; Boado RJ; Pardridge WM
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14709-14. PubMed ID: 11106372
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Evaluation of (99m)Tc-Epidermal Growth Factor Receptor (EGFR)-Peptide Nucleic Acid for Visualization of EGFR Messenger RNA Expression in Malignant Tumors.
Zhao X; Wang N; Ren X; Zhang J; Wang J; Han J; Jia L; Liu Y; Zhang Z
J Nucl Med; 2014 Jun; 55(6):1008-16. PubMed ID: 24744447
[TBL] [Abstract][Full Text] [Related]
12. Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
Jia F; Balaji BS; Gallazzi F; Lewis MR
Nucl Med Biol; 2015 Nov; 42(11):809-15. PubMed ID: 26239085
[TBL] [Abstract][Full Text] [Related]
13. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
14. Pretargeting with amplification using polymeric peptide nucleic acid.
Wang Y; Chang F; Zhang Y; Liu N; Liu G; Gupta S; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2001; 12(5):807-16. PubMed ID: 11562199
[TBL] [Abstract][Full Text] [Related]
15. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.
Wu D; Yang J; Pardridge WM
J Clin Invest; 1997 Oct; 100(7):1804-12. PubMed ID: 9312181
[TBL] [Abstract][Full Text] [Related]
16. Sequence-specific DNA strand cleavage by 111In-labeled peptide nucleic acids.
He Y; Panyutin IG; Karavanov A; Demidov VV; Neumann RD
Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):837-45. PubMed ID: 14762696
[TBL] [Abstract][Full Text] [Related]
17. OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma.
Yue PJ; He L; Qiu SW; Li Y; Liao YJ; Li XP; Xie D; Peng Y
Mol Cancer; 2014 Aug; 13():191. PubMed ID: 25128329
[TBL] [Abstract][Full Text] [Related]
18. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier.
Kurihara A; Pardridge WM
Cancer Res; 1999 Dec; 59(24):6159-63. PubMed ID: 10626807
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
20. Radiometal-labeled peptide-PNA conjugates for targeting bcl-2 expression: preparation, characterization, and in vitro mRNA binding.
Lewis MR; Jia F; Gallazzi F; Wang Y; Zhang J; Shenoy N; Lever SZ; Hannink M
Bioconjug Chem; 2002; 13(6):1176-80. PubMed ID: 12440850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
